Cargando…

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis

The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Branković, Marija, Jovanović, Igor, Dukić, Marija, Radonjić, Tijana, Oprić, Svetlana, Klašnja, Slobodan, Zdravković, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105530/
https://www.ncbi.nlm.nih.gov/pubmed/35563534
http://dx.doi.org/10.3390/ijms23095146
_version_ 1784708062880202752
author Branković, Marija
Jovanović, Igor
Dukić, Marija
Radonjić, Tijana
Oprić, Svetlana
Klašnja, Slobodan
Zdravković, Marija
author_facet Branković, Marija
Jovanović, Igor
Dukić, Marija
Radonjić, Tijana
Oprić, Svetlana
Klašnja, Slobodan
Zdravković, Marija
author_sort Branković, Marija
collection PubMed
description The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxicity can influence the accumulation of reactive oxygen species (ROS), so oxidative stress is also crucial for the progression of NASH. Moreover, NASH is in strong connection with metabolic disorders, and supporting evidence shows that insulin resistance (IR) is in a close relation to NAFLD, as it is involved in the progression to NASH and further progression to hepatic fibrosis. The major issue is that, at the moment, NASH treatment is based on lifestyle changes only due to the fact that no approved therapeutic options are available. The development of new therapeutic strategies should be conducted towards the potential NAFLD and NASH treatment by the modulation of IR but also by dietary antioxidants. As it seems, NASH is going to be the leading indication for liver transplantation as a consequence of increased disease prevalence and the lack of approved treatment; thus, an effective solution is needed as soon as possible.
format Online
Article
Text
id pubmed-9105530
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91055302022-05-14 Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis Branković, Marija Jovanović, Igor Dukić, Marija Radonjić, Tijana Oprić, Svetlana Klašnja, Slobodan Zdravković, Marija Int J Mol Sci Review The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxicity can influence the accumulation of reactive oxygen species (ROS), so oxidative stress is also crucial for the progression of NASH. Moreover, NASH is in strong connection with metabolic disorders, and supporting evidence shows that insulin resistance (IR) is in a close relation to NAFLD, as it is involved in the progression to NASH and further progression to hepatic fibrosis. The major issue is that, at the moment, NASH treatment is based on lifestyle changes only due to the fact that no approved therapeutic options are available. The development of new therapeutic strategies should be conducted towards the potential NAFLD and NASH treatment by the modulation of IR but also by dietary antioxidants. As it seems, NASH is going to be the leading indication for liver transplantation as a consequence of increased disease prevalence and the lack of approved treatment; thus, an effective solution is needed as soon as possible. MDPI 2022-05-05 /pmc/articles/PMC9105530/ /pubmed/35563534 http://dx.doi.org/10.3390/ijms23095146 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Branković, Marija
Jovanović, Igor
Dukić, Marija
Radonjić, Tijana
Oprić, Svetlana
Klašnja, Slobodan
Zdravković, Marija
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title_full Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title_fullStr Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title_full_unstemmed Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title_short Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
title_sort lipotoxicity as the leading cause of non-alcoholic steatohepatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105530/
https://www.ncbi.nlm.nih.gov/pubmed/35563534
http://dx.doi.org/10.3390/ijms23095146
work_keys_str_mv AT brankovicmarija lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT jovanovicigor lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT dukicmarija lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT radonjictijana lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT opricsvetlana lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT klasnjaslobodan lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis
AT zdravkovicmarija lipotoxicityastheleadingcauseofnonalcoholicsteatohepatitis